Common effect measures in medical and economic studies? Results of an exploratory survey of physicians;Gemeinsame effektmasse in medizinischen und gesundheitsokonomischen studien? Ergebnisse einer explorativen arztebefragung

Medizinische Klinik

Volumn 94, Issue 12, 1999, Pages 665-672

  König, Hans Helmut ^a   Hoffmann, Christiane ^b   Von Der Schulenburg, J Matthias Graf ^b   Leidl, Reiner ^b  

^a UNIVERSITY OF ULM   (Germany)

^b NONE

Author keywords

Clinical and economic end points; Cost utility analysis; Economic evaluation; Health related quality of life; Quality adjusted life year (QALY)

Indexed keywords

ARTICLE; CLINICAL PRACTICE; COST UTILITY ANALYSIS; HEALTH ECONOMICS; HUMAN; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE;

EID: 0343851698     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03044756     Document Type: Article

References (18)

1. Abbühl B. EUROMET-Projektgruppe. Österreich. (Pers. Mitt., 1999).
2. Aday LU. Designing and conducting health surveys. San Francisco: Josey-Bass, 1989.
3. American Society of Clinical Oncology. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol 1996;14:671-9.
4. Anderson H, Palmer MK. Measuring quality of life: impact of chemotherapy for advanced colorectal cancer. Experience from two recent large phase III trials. Br J Cancer 1998;77:Suppl 2:9-14.
5. Bergner M, Bobbit RA, Carter WB, et al. The sickness impact profile: development and final revision of a health status measure. Med Care 1981;19:787-805.
6. Breyer F, Leidl K. Wozu dient Evaluation im Gesundheitswesen. In: Knappe E, Hrsg. Reformstrategie "Managed Care", Baden-Baden: Nomos, 1998:121-37.
7. Brooks R. EuroQol: the current state of play. Hlth Policy 1996;37:53-72.
8. Casali P, Licitra L, Costantini M, et al. Quality of life assessment and clinical decision-making. Ann Oncol 1997;8:1207-11.
9. Dolan P. The effect of experience of illness on health state valuations. J Clin Epidemiol 1996;49:551-64.
10. Earlam S, Glover C, Davies M, et al. Effect of regional and systemic flourinated pyrimidine chemotherapy on quality of life in colorectal liver metastasis patients. J Clin Oncol 1997;15:2022-9.
11. Kaplan RM, Anderson JP. The general health policy model: an integrated approach. In: Spilker B, ed. Quality of life assessments in clinical trials. New York: Raven Press, 1990:131-49.
12. Mehrez A, Gafni A. Quality-adjusted life years, utility theory, and healthy-years equivalents. Med Decis Making 1989;9:142-9.
13. Morris J, Perez D, McNoe B. The use of quality of life data in clinical practice. Qual Life Res 1998;7:85-91.
14. Slevin ML, Plant H, Lynch D, et al. Who should measure quality of life, the doctor or the patient? Br J Cancer 1988;57:109-12.
15. Taylor KM, Macdonald KC, Bezjak A, et al. Physicians' perspective on quality of life: an explorative study of oncologists. Qual Life Res 1996;5:5-13.
16. Torrance GW, Feeny DH, Furlong WJ, et al. Multi-attributive utility function for a comprehensive health status classification system. Med Care 1996;34:702-22.
17. Ware JE, Gandek B. Overview of the SF-36 health survey and the international quality of life assessment (IQO-LA) project. J Clin Epidemiol 1998;51:903-12.
18. Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996;276:1253-8.